D3 Selective Piperazine Compounds for Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing dopamine D3 receptor ligands with selectivity over D2 receptors is challenging due to their high structural homology, making it difficult to predict affinity and selectivity profiles, especially with piperazine head groups and aromatic tail groups.
Innovation Solution
New compounds represented by Formula I, which include an unbranched hydrocarbon chain, aryl groups, and heterocyclic moieties, are synthesized to display D3 receptor binding selectivity and antagonist or partial agonist functional activity, using 4-aminobutyl piperazines reacted with carbonyldiimidazole and secondary amines or acids to form amides and ureas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If D3 selective ligands are developed to treat neurological disorders, then therapeutic efficacy is improved, but structural homology between D2 and D3 receptors makes selectivity prediction difficult
Solution Approach 1:
The ligand molecule is divided into distinct functional segments: a piperazine head group (formula II) that interacts with the orthosteric binding site, a linker region (Y chain with 2-5 carbon atoms), and an aromatic tail group (R1) that occupies the accessory binding pocket. This segmentation allows independent optimization of each region to achieve D3 selectivity despite overall structural homology between receptors.
Solution Approach 2:
Different regions of the ligand are assigned specific structural qualities: the piperazine nitrogen atoms provide basic centers for ionic interactions, the Y chain provides flexible spacing, and the aromatic R1 group (such as pyrimidinyl with tert-butyl and trifluoromethyl substituents) provides pi-stacking and hydrophobic interactions specific to the D3 accessory pocket, creating local structural features that differentiate binding affinity.
2Reliability
If piperazine head groups with aromatic tail groups are used, then D3 binding affinity is improved, but affinity and selectivity profiles become difficult to predict
Solution Approach 1:
Systematic variation of key molecular parameters is employed: the Y chain length is restricted to 2-5 carbon atoms to optimize spacing, R1 is selected from specific heteroaryl groups (pyrimidinyl, pyridinyl, quinolinyl) with defined electronic and steric properties, and substituents like tert-butyl and trifluoromethyl are positioned at specific locations (2- and 6-positions of pyrimidinyl) to fine-tune binding characteristics and achieve predictable high-affinity D3 interaction.
3Reliability
If D3 antagonists are used to treat schizophrenia, then positive symptoms are attenuated, but extrapyramidal side effects may occur
Solution Approach 1:
The compounds act as selective intermediaries that preferentially bind to D3 receptors over D2 receptors. The specific structural features (pyrimidinyl R1 group with tert-butyl and trifluoromethyl substituents, combined with the piperazine-Y chain architecture) serve as a molecular key that fits the D3 lock more precisely than the D2 lock, enabling therapeutic action at D3 sites while sparing D2 sites from blockade, thus avoiding extrapyramidal side effects.
Data Source
AI summary
Provided are compounds represented by the formula: with Y, Ri, and R2 being defined in the present disclosure; pharmaceutically acceptable salts thereof, deuterated forms thereof, isomers thereof, solvates thereof, and mixtures thereof. The compounds can be used for treating a patient suffering from a condition capable of treatment with a partial agonist or antagonist of the dopamine D2/D3 receptors and are especially useful for patients suffering from schizophrenia, depressions, neurodegenerative diseases such as Parkinson's, dyskinesias, substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol, glaucoma, cognitive disorders, restless leg syndrome, attention deficit hyperactivity disorders, hyperprolactinemia, autism, motor disturbances such as akathisia, rigor, dystonias as well as various disorders of the urinary tract and other neurologic disorders. Also provided are processes for the preparation of compounds of the present disclosure.